Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? - Wikidata - awgldk - TriplyDB

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

http://www.wikidata.org/entity/Q37225766

about

Trial Watch-Immunostimulation with cytokines in cancer therapy Pancreatic cancer, treatment options, and GI-4000 Trial watch: Immunostimulatory cytokines in cancer therapy.Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma Pancreatic cancer, treatment options, and GI-4000.Probable involvement of p11 with interferon alpha induced depression Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.Immunotherapeutic approaches for cancer therapy: An updated review.The Role of IFN-alpha in Experimental and Clinical Uveitis.The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Potassium Ascorbate with Ribose: Promising Therapeutic Approach for Melanoma Treatment.

P2860

Q28078725-1D0DAFF5-F03C-4297-892A-FB1209343A2A Q28083814-52528202-983B-4F5D-B8D6-0A85FF4AF24D Q33880165-390ED070-313D-48C0-8F8D-6B0F216516F3 Q33933053-F3FC5CDB-2715-4E22-A8EE-B7069F9EE715 Q34000700-85ACC3FE-313A-4CD3-8AE5-29DD0869B95F Q34114136-07D3297B-4151-4C87-9074-DAB82C92D965 Q34646279-092514DD-5463-4264-971B-6C7C7C1DF4A2 Q35887099-97F058E5-50AA-4FE4-A3C1-F3CD63421BC8 Q36517077-25280391-0F3C-40E4-8C0F-0C7C99ECAEDC Q36779843-5343489E-2FB1-46B0-B0AD-910D38C80052 Q37641495-E887BD98-BA62-4908-B266-DB32340A7D80 Q38388102-11CBB500-DA34-4B21-9AFF-DC3911344248 Q38856516-ACE7EA73-4538-46D5-9CC1-28F6141642EB Q39024088-98DFBD7D-9C30-4F57-B498-6E7D19CEDF95 Q39945198-135E9492-48C9-43DC-812E-2B43F4063616 Q42702234-F3F30686-714F-4DA6-B74D-E84EA3C0392E Q47151869-66C4F00F-2E5B-4D3F-B160-F22B20DB6AE2

P2860

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

http://www.wikidata.org/entity/Q37225766

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

@en

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

@nl

type

label

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

@en

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

@nl

prefLabel

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

@en

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

@nl

P1433

Q37225766-8F1EA333-35DF-49ED-8C65-8E7F6557B01B

P1476

Q37225766-43B1A3B6-7335-4912-968E-925A1C9CFE9B

P2093

Q37225766-BE2220C7-3FF1-4333-871B-330E15BFF7C1

P2860

Q37225766-133ED8B1-3434-4C8D-A9A5-AC35B38B7B4C

Q37225766-2EA2FC96-D7C6-4171-BACB-3D52C401CE83

Q37225766-38A33131-84AA-46AA-BEF2-B4E815E428CA

Q37225766-5147ECCD-E86C-431E-B954-79C014B434EB

Q37225766-538209A5-3E4E-4CE4-A455-5565D5B1E4E9

Q37225766-6CE27F66-807C-41FE-A271-293EFF28F39E

Q37225766-6D2D3F0A-4FAA-4F80-8ACA-74493893D386

Q37225766-B5E8B45D-0EFE-49EF-9C55-110DE02D8F99

Q37225766-FD29D676-E751-422B-A1CE-476D06CC6A09

P304

Q37225766-FDE0944E-D858-47ED-9FB1-41AC2E574B0B

P31

Q37225766-BB864C06-2A0C-4E4F-87DA-29D311FB3DD6

Q37225766-a270800b-fd5e-4e48-b190-d142401c9234

P356

Q37225766-61196B5E-F976-4149-B370-B9C0DF234D0E

P433

Q37225766-BADCC183-3679-45F2-B9C0-513F37A20205

P478

Q37225766-1ED5629B-CEA2-427F-9114-DADA4E18411A

P577

Q37225766-12DEE70E-DAEA-404F-B4E2-581AD245018C

P5875

Q37225766-8EE3EE94-2A25-4E34-9A66-146956378D35

P698

Q37225766-5D43729F-A05D-4F19-9DB3-1C6786371601

P932

Q37225766-D8E477AD-D04E-47F1-997B-A6C5E07682CB

P356

P1433

Current Oncology

P1476

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

@en

P2093

A Hauschild

http://www.w3.org/2001/XMLSchema#string

P2860

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.

New promises in the adjuvant, and palliative treatment of melanoma.

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.

P304

3-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.V16I3.447

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26291687

http://www.w3.org/2001/XMLSchema#string

P698

19526078

http://www.w3.org/2001/XMLSchema#string

P932

2695706

http://www.w3.org/2001/XMLSchema#string